QS Investors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

QS Investors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$243K	Sell	35,700 -700	-2%	-$5.82K	﹤0.01%	1008
2021 Q1	$374K	Buy	36,400 +17,000	+88%	+$186K	﹤0.01%	903
2020 Q4	$136K	Hold	19,400	–	–	﹤0.01%	1127
2020 Q3	$159K	Sell	19,400 -81,500	-81%	-$505K	﹤0.01%	1095
2020 Q2	$697K	Hold	100,900	–	–	0.01%	830
2020 Q1	$480K	Hold	100,900	–	–	0.01%	852
2019 Q4	$878K	Sell	100,900 -1,500	-1%	-$8.11K	0.01%	813
2019 Q3	$341K	Hold	102,400	–	–	﹤0.01%	1052
2019 Q2	$507K	Sell	102,400 -2,300	-2%	-$12.2K	0.01%	968
2019 Q1	$650K	Buy	104,700 +103,300	+7,379%	+$499K	0.01%	922
2018 Q4	$5K	Buy	+1,400	New	+$6.54K	﹤0.01%	1581

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

QS Investors's JNCE Position: Q2 2021 in Review

QS Investors reduced its Jounce Therapeutics, Inc. Common Stock (JNCE) stake by 1.9% in Q2 2021, selling an estimated $5.82K and leaving 35,700 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

QS Investors first reported a position in JNCE in Q4 2018 and has held it in 11 quarters since. The position peaked at $878K in Q4 2019. 130 funds tracked by Wall St. Rank hold JNCE as of Q2 2021.

QS Investors held 35,700 shares of Jounce Therapeutics, Inc. Common Stock worth $243K as of Q2 2021.
QS Investors sold 700 Jounce Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5.82K.
Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #1008 holding.
QS Investors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and has held it in 11 quarters since.
QS Investors's Jounce Therapeutics, Inc. Common Stock position peaked at $878K in Q4 2019.
130 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.